Page advises public companies on capital-raising transactions, SEC reporting and corporate governance. Page also counsels public and private companies on a broad range of executive compensation and equity compensation arrangements and programs, including equity and incentive plans and related tax, corporate and securities law concerns.
Page concentrates her practice on the life sciences and technology sectors, including representing pharmaceutical, biotech and medical device companies.
She represents issuers in IPOs, de-SPAC and reverse merger transactions, follow-on public offerings, ATM offerings, registered directs and PIPEs. Page also has experience representing buyers and sellers in mergers and acquisitions, spinoffs and private equity investments. As part of her practice advising public companies, Page helps clients navigate corporate governance and securities compliance obligations, ESG matters, Nasdaq and NYSE listing requirements, proxy advisory firm policies, and rules regarding disclosure of director and executive compensation.
Page also has an active pro bono practice. She has represented clients in applications for political asylum in the United States and represented asylum candidates in bond hearings.
viewpoints
Preparation for 2024 Fiscal Year-End SEC Filings and 2025 Annual Shareholder Meetings
December 17, 2024 | Advisory | By Anne Bruno, Daniel T. Kajunski, Melanie Ruthrauff Levy, Page R. Hubben, David Adams, Joanne Hawana , Jacob Hupart, Cynthia Larose, Breton Leone-Quick, Benjamin Zegarelli, Christopher Buontempo
An analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission (SEC) and their annual shareholder meetings. This memorandum discusses key considerations to keep in mind as you embark upon the year-end reporting process in 2025.
SEC Approves Nasdaq Rule Change on Reverse Stock Splits and Minimum Bid Price Compliance Timing
October 17, 2024 | Alert | By Page R. Hubben, Anne Bruno, Daniel T. Kajunski
Read about an amendment to Nasdaq Listing Rule 5810(c)(3)(A), approved by the SEC on October 7, 2024, which affects companies utilizing reverse stock splits to regain compliance with Nasdaq’s minimum bid price requirements.
New Schedule 13G Accelerated Filing Deadlines Effective Today, September 30, 2024
September 30, 2024 | Alert | By Page R. Hubben, Daniel T. Kajunski, Anne Bruno
Read about the new accelerated filing deadlines for ownership reporting on Schedule 13G that take effect on September 30, 2024 and the requirements for different types of investors.
Preparation for 2023 Fiscal Year-End SEC Filings and 2024 Annual Shareholder Meetings
December 15, 2023 | Advisory | By John Condon, Anne Bruno, Melanie Ruthrauff Levy, Jacob Hupart, Cynthia Larose, Breton Leone-Quick, Page R. Hubben, Ellen Shapiro
Public companies need to consider regulatory, legal, market, and ESG-related developments in preparing for their fiscal year-end filings with the SEC and their annual shareholder meetings. In an in-depth memorandum, Mintz attorneys discuss the SEC’s new cybersecurity disclosure rule, recent trends in reverse stock splits, and the SEC’s disclosure requirements for Rule 10b5-1 trading plans and insider trading policies, and other emerging issues affecting public companies.